Nsabp b39 trial

Investigation of helical tomotherapy for partial-breast irradiation of prone-positioned patients. Investigation of accelerated partial breast patient alignment and treatment with helical tomotherapy unit.

Epub Jan J Appl Clin Med Phys. Dickler A. The MammoSite breast brachytherapy device: targeted delivery of breast brachytherapy. Future Oncol. Sanghani M, Wazer DE. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Epub Dec 5. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Breast Cancer. Radiation: 3-dimensional conformal accelerated partial breast irradiation Radiation: brachytherapy Radiation: whole breast irradiation Radiation: MammoSite or other single-entry intracavitary device. Not Applicable. Study Type :. Interventional Clinical Trial. Actual Enrollment :. Study Start Date :. Actual Primary Completion Date :. Estimated Study Completion Date :. Radiation: whole breast irradiation Patients undergo radiation therapy once daily days for up to 7 weeks.

Radiation: 3-dimensional conformal accelerated partial breast irradiation Radiation: brachytherapy Radiation: MammoSite or other single-entry intracavitary device. Los Angeles, California, United States, Ruby L. Colorado Springs, Colorado, United States, Hartford, Connecticut, United States, New Haven, Connecticut, United States, Washington, District of Columbia, United States, Eugene M.

Jacksonville Beach, Florida, United States, Charles B. Mountain States Tumor Institute at St. Luke's Regional Medical Center. Downers Grove, Illinois, United States, Lucille P. Markey Cancer Center at University of Kentucky. Clinton Township, Michigan, United States, Van Elslander Cancer Center at St. John Hospital and Medical Center.

Robbinsdale, Minnesota, United States, Montana Cancer Center at St. Patrick Hospital and Health Sciences Center. There were no treatment-related deaths.

Second cancers and treatment-related toxicities were similar between the two groups. Our trial had broad eligibility criteria, leading to a large, heterogeneous pool of patients and sufficient power to detect treatment equivalence, but was not designed to test equivalence in patient subgroups or outcomes from different APBI techniques.

Abstract Background: Whole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence IBTR , yielding comparable results to mastectomy.

No No. Clinical Clinical. Autopsy Autopsy. Has the patient had a documented clinical assessment for this cancer since submission of the last follow-up form?

Date of Last Clinical Assessment if applicable. Has the patient been diagnosed with first local-regional recurrence since submission of the last follow-up form? Date of First Local-Regional Recurrence if applicable. Ipsilateral Breast Ipsilateral breast. Chest Wall Chest wall.

Axilla Axilla. Date of First Distant Recurrence if applicable. Site s of First Distant Recurrence. Has a new primary cancer or MDS been diagnosed that has not been previously reported? Date of Diagnosis if applicable. Site s of New Primary. Serm SERM. Aromatase Inhibitor Aromatase inhibitor. Total Mastectomy Date ipsilateral breast only.